IP Library Granted Patent US 9,187,733
Granted Patent B2
US 9,187,733 · App. 13/768,933 · Granted Nov 17, 2015

Anti-cancer adenoviruses

Inventors: Clodagh O'Shea (San Diego, CA); Colin Powers (San Diego, CA)
Assignee: Salk Institute for Biological Studies
C12N7/04A61K35/761C12N7/00C12N2710/10322C12N2710/10332
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,187,733
App. No.
13/768,933
Granted
Nov 17, 2015
Kind
B2
Abstract

Anti-cancer adenoviruses, methods of use and methods of making the same are provided herein.

Claims (9)

1. A method of treating a cancer with reduced expression or activity of p53, comprising administering an effective amount of a recombinant adenovirus that is E1B-55k impaired and E4-ORF3 impaired to a subject in need thereof, wherein the recombinant adenovirus is not replication impaired in a p53 impaired cell.

2. The method of claim 1 , wherein the cancer is lung cancer, skin cancer or breast cancer.

3. The method of claim 1 , wherein the cancer to be treated is pre-malignant breast cancer.

4. The method of claim 1 , wherein the recombinant adenovirus expresses a mutated E4-ORF3 product.

5. The method of claim 1 , wherein the recombinant adenovirus comprises an E4-ORF3 gene that is wholly or partially deleted.

6. The method of claim 1 , wherein the recombinant adenovirus expresses a mutated E1B-55k gene product.

7. The method of claim 1 , wherein the recombinant adenovirus comprises an E1B-55k gene that is wholly or partially deleted.

8. The method of claim 1 , wherein the recombinant adenovirus comprises an E4-ORF3 gene that is wholly or partially deleted and an E1B-55k gene that is wholly or partially deleted.

9. The method of claim 1 , wherein the recombinant adenovirus comprises a mutated E4-ORF3 gene and an E1B-55k gene that is wholly or partially deleted.

Assignments (3)
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 2, 2026
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 074994/0338 →
CONFIRMATORY LICENSE Recorded Mar 19, 2015
From: SALK INSTITUTE FOR BIOLOGICAL STUDIES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035223/0899 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2014
From: O'SHEA, CLODAGH; POWERS, COLIN
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 034210/0263 →
Continuity (3)
Continuation PCTUS2011048005 · Aug 16, 2011
Provisional Application 61374215 · Aug 16, 2010
Related Publication 20130243729A1 · Sep 19, 2013